Growth pattern of uterine leiomyoma along pregnancy.


Journal

BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690

Informations de publication

Date de publication:
22 07 2019
Historique:
received: 05 06 2019
accepted: 12 07 2019
entrez: 24 7 2019
pubmed: 25 7 2019
medline: 30 11 2019
Statut: epublish

Résumé

Uterine leiomyomas are often discovered during early pregnancy and in most cases will have no effect on pregnancy outcomes. However, in rare cases uterine leiomyomas may lead to obstetric complications. The aim of the study was to evaluate rate of uterine leiomyoma growth in the 3 trimesters of pregnancy. We conducted a retrospective cohort study. Included were women who were diagnosed with uterine leiomyoma during pregnancy and had at least two sonographic measurements in different trimesters. Data regarding leiomyoma growth, recorded by ultrasound examination, during 1st 2nd and 3rd trimesters were collected from electronic patient records. Two-hundred forty-eight uterine leiomyomas were included in the study. Leiomyoma area increased substantially in size between the 1st and 2nd trimesters (54.5% ± 75.9%, p = .007) and to a lesser degree between the 2nd and 3rd trimesters (17.9% ± 59.7%, NS). Evaluation of the change in size throughout the pregnancy - between 1st and 3rd trimesters revealed a significant increase of 95.9% ± 191.3% (p < .001). There was no significant growth of the leiomyomas between the 2nd and 3rd trimesters. Uterine leiomyomas tend to grow substantially during the 1st trimester of pregnancy. This trend is attenuated later with minimal growth towards the end of gestation.

Sections du résumé

BACKGROUND
Uterine leiomyomas are often discovered during early pregnancy and in most cases will have no effect on pregnancy outcomes. However, in rare cases uterine leiomyomas may lead to obstetric complications. The aim of the study was to evaluate rate of uterine leiomyoma growth in the 3 trimesters of pregnancy.
METHODS
We conducted a retrospective cohort study. Included were women who were diagnosed with uterine leiomyoma during pregnancy and had at least two sonographic measurements in different trimesters. Data regarding leiomyoma growth, recorded by ultrasound examination, during 1st 2nd and 3rd trimesters were collected from electronic patient records.
RESULTS
Two-hundred forty-eight uterine leiomyomas were included in the study. Leiomyoma area increased substantially in size between the 1st and 2nd trimesters (54.5% ± 75.9%, p = .007) and to a lesser degree between the 2nd and 3rd trimesters (17.9% ± 59.7%, NS). Evaluation of the change in size throughout the pregnancy - between 1st and 3rd trimesters revealed a significant increase of 95.9% ± 191.3% (p < .001). There was no significant growth of the leiomyomas between the 2nd and 3rd trimesters.
CONCLUSIONS
Uterine leiomyomas tend to grow substantially during the 1st trimester of pregnancy. This trend is attenuated later with minimal growth towards the end of gestation.

Identifiants

pubmed: 31331317
doi: 10.1186/s12905-019-0803-5
pii: 10.1186/s12905-019-0803-5
pmc: PMC6647306
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100

Références

Lancet. 2001 Jan 27;357(9252):293-8
pubmed: 11214143
Acta Obstet Gynecol Scand. 1985;64(4):307-9
pubmed: 4024879
Obstet Gynecol. 2009 Mar;113(3):630-5
pubmed: 19300327
Obstet Gynecol. 1989 Apr;73(4):593-6
pubmed: 2927854
Hum Reprod Update. 2004 May-Jun;10(3):207-20
pubmed: 15140868
Obstet Gynecol. 1993 Jul;82(1):97-101
pubmed: 8515934
Obstet Gynecol. 2004 Aug;104(2):393-406
pubmed: 15292018
Radiology. 1987 Aug;164(2):375-80
pubmed: 3299488
Br J Obstet Gynaecol. 1988 May;95(5):510-3
pubmed: 3042016
Arch Gynecol Obstet. 2018 Apr;297(4):823-835
pubmed: 29236171
J Reprod Med. 2006 Sep;51(9):671-4
pubmed: 17039693
Aust N Z J Obstet Gynaecol. 2012 Jun;52(3):258-61
pubmed: 22360538
Fertil Steril. 2016 May;105(5):1255-1260
pubmed: 26876103
Mol Cell Endocrinol. 2007 Apr 15;269(1-2):51-60
pubmed: 17367919
Obstet Gynecol. 2006 Feb;107(2 Pt 1):376-82
pubmed: 16449127
Int J Mol Sci. 2017 Sep 20;18(9):
pubmed: 28930160
Ultrasound Obstet Gynecol. 2011 Mar;37(3):361-5
pubmed: 20922776

Auteurs

Henry Hillel Chill (HH)

Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Center, Ein-Kerem, PO Box 12000, 91120, Jerusalem, Israel. henchill@gmail.com.

Gilad Karavani (G)

Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Center, Ein-Kerem, PO Box 12000, 91120, Jerusalem, Israel.

Talya Rachmani (T)

Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Center, Ein-Kerem, PO Box 12000, 91120, Jerusalem, Israel.

Uri Dior (U)

Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Center, Ein-Kerem, PO Box 12000, 91120, Jerusalem, Israel.

Ofer Tadmor (O)

Maccabi Health Services, Jerusalem, Israel.

Asher Shushan (A)

Department of Obstetrics and Gynecology, Hadassah Hebrew University Medical Center, Ein-Kerem, PO Box 12000, 91120, Jerusalem, Israel.
Maccabi Health Services, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH